Lucinda Warren - 03 Sep 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ Lucinda Warren by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
03 Sep 2024
Net transactions value
$0
Form type
4
Filing time
05 Sep 2024, 16:00:02 UTC
Next filing
25 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +350,000 $0.000000 350,000 03 Sep 2024 Common Stock 350,000 $0.6600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in four equal semi-annual installments beginning on March 3, 2025.